Inebilizumab Effective Up to 52 Weeks in Myasthenia Gravis ...Middle East

Medscape - News
Inebilizumab Effective Up to 52 Weeks in Myasthenia Gravis
Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests. Medscape Medical News

Hence then, the article about inebilizumab effective up to 52 weeks in myasthenia gravis was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Inebilizumab Effective Up to 52 Weeks in Myasthenia Gravis )

Apple Storegoogle play

Last updated :

Also on site :